EUVIMEDObjevte EUVIMED
Klinische Studie (Phase III)Multizentrische StudieVergleichsstudieRandomisierte kontrollierte StudieOpen access · CC BY-NC-ND 4.0

Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study

Weijun Fu, Soo-Mee Bang, Honghui Huang, Kihyun Kim, Wei Li, Gang An, Je-Jung Lee, Zhen Cai, Jie Jin, Yafei Wang, Chor Sang Chim, Robin Carson and 6 more

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05958-8 ↗

At a glance

Klinische Studie (Phase III) in Annals of Hematology, 2024. Written by Weijun Fu and 17 co-authors. Institution: Shanghai Changzheng Hospital, Shanghai, China. Major MEDLINE topics: Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Multiple Myeloma. Cited 7 times so far (Crossref); 23 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Janssen Research & Development, LLC.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Není k dispozici žádný abstrakt.

Subjects

MeSH terms (MEDLINE)

Antibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsMultiple MyelomaAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedBortezomibFollow-Up StudiesMelphalanPrednisoneEast Asian People

Author keywords

DaratumumabMinimal residual diseaseMultiple myelomaResponseSafetySurvival

Substances

Antibodies, MonoclonalBortezomibdaratumumabMelphalanPrednisone

Authors and institutions

  • Shanghai Changzheng Hospital, Shanghai, China.
  • Seoul National University Bundang Hospital, Seongnam, South Korea.
  • Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • First Hospital of Jilin University, Changchun, China.
  • Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.

Funding

  • Janssen Research & Development, LLC

Cite

APA

Fu, W., Bang, S. M., Huang, H., Kim, K., Li, W., An, G., Lee, J. J., Cai, Z., Jin, J., Wang, Y., Chim, C. S., Carson, R., Liu, R., Zhao, M., Chen, X., Cui, C., Hou, J., & Wang, J. (2024). Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study. Annals of Hematology. https://doi.org/10.1007/s00277-024-05958-8

Vancouver

Fu W, Bang SM, Huang H, Kim K, Li W, An G, et al. Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study. Annals of Hematology. 2024. doi:10.1007/s00277-024-05958-8

BibTeX
@article{Fu2024,
  author = {Fu, Weijun and Bang, Soo-Mee and Huang, Honghui and Kim, Kihyun and Li, Wei and An, Gang and Lee, Je-Jung and Cai, Zhen and Jin, Jie and Wang, Yafei and Chim, Chor Sang and Carson, Robin and Liu, Rui and Zhao, Man and Chen, Xi and Cui, Canchan and Hou, Jian and Wang, Jianxiang},
  title = {Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05958-8}
}
Start for free →